Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Calcitriol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 10/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | GC | P02774 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | RXRA | P19793 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Calcitriol SCHEMBL3488822 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL2641696 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL2733051 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL15169024 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL24066838 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL14027727 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL23386523 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL13989116 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL17973736 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL21055106 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0998925-A1 | MEDICINAL COMPOSITIONS FOR TOPICAL ADMINISTRATION CONTAINING VITAMIN D AND VITAMIN K | New Vision Co., Ltd. (JP) | 2000-05-10 | — | — | EP | claimed |
| US-7704979-B2 | Materials and methods for the treatment or prevention of obesity | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2010-04-27 | — | — | US | disclosed |
| US-20020192264-A1 | Materials and methods for the treatment or prevention of obesity | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION | 2002-12-19 | — | — | US | disclosed |
| US-6329357-B1 | VITAMIN DEFFICIENCY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-12-11 | — | — | US | disclosed |
| US-6307075-B2 | SELECTIVE AGONISTS FOR THE GENOMIC RESPONSES OR AGONISTS OR ANTAGONISTS FOR THE RAPID CELLULAR RESPONSES IN A WIDE ARRAY OF DISEASES; TREATMENT AND PREVENTION OF DISEASES CONNECTED WITH THE ENDOCRINE SYSTEM. | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-10-23 | — | — | US | disclosed |
| US-20010014749-A1 | THERAPEUTICALLY EFFECTIVE 1ALPHA,25-DIHYDROXYVITAMIN D3 ANALOGS | NORMAN ANTHONY W (US) | 2001-08-16 | — | — | US | disclosed |
| EP-1059085-A1 | LANGERHANS CELL MIGRATION INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-12-13 | — | — | EP | disclosed |
| EP-1021193-A1 | THERAPEUTICALLY EFFECTIVE 1$g(a), 25-DIHYDROXYVITAMIN D 3? ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-0998925-A1 | MEDICINAL COMPOSITIONS FOR TOPICAL ADMINISTRATION CONTAINING VITAMIN D AND VITAMIN K | New Vision Co., Ltd. (JP) | 2000-05-10 | — | — | EP | disclosed |
| WO-1999016452-A1 | THERAPEUTICALLY EFFECTIVE 1α, 25-DIHYDROXYVITAMIN D3 ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-04-08 | — | — | WO | disclosed |
| EP-0506388-B1 | 1-Hydroxyvitamin D derivatives | NISSHIN FLOUR MILLING CO (JP) | 1996-06-05 | — | — | EP | disclosed |
| US-5182396-A | Osteoporosis, antiulcer, antitumor | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1993-01-26 | — | — | US | disclosed |
| EP-0506388-A1 | 1-Hydroxyvitamin D derivatives | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1992-09-30 | — | — | EP | disclosed |
| EP-0278732-B1 | FLUORINE-CONTAINING VITAMIN D2 DERIVATIVES | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1992-01-08 | — | — | EP | disclosed |
| EP-0278732-A1 | Fluorine-containing vitamin D2 derivatives | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1988-08-17 | — | — | EP | disclosed |
| US-4267117-A | INTERMEDIATES FOR 1A-HYDROXYLATED CALCIFEROLS | THE UPJOHN COMPANY (US) | 1981-05-12 | — | — | US | disclosed |
| US-4206131-A | 1A-HYDROXYLATED CALCIFEROLS | THE UPJOHN COMPANY (US) | 1980-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014749-A1 | THERAPEUTICALLY EFFECTIVE 1ALPHA,25-DIHYDROXYVITAMIN D3 ANALOGS | VDR, CYP24A1, CYP2R1 | VDR 1/4885MAPT 4770/4885ADORA3 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.